Last updated: January 24, 2026
Executive Summary
This case involves patent infringement allegations filed by Genentech, Inc. against Laurus Labs Ltd., concerning biosimilar versions of the blockbuster drug Avastin (bevacizumab). The dispute centers on the validity and infringement of key patent rights held by Genentech, specifically targeting biosimilar development and sales. The proceedings, initiated in the United States District Court for the District of Delaware, highlight critical patent issues relevant to biosimilar entry, patent term strategies, and litigation tactics within the biopharmaceutical industry.
Key Highlights:
- Case number: 1:19-cv-00104
- Filed: January 10, 2019
- Parties: Genentech, Inc. (Plaintiff) vs. Laurus Labs Ltd. (Defendant)
- Core Issue: Patent infringement related to biosimilar versions of bevacizumab
- Legal focus: Patent validity, infringement, early settlement negotiations, and potential remedies
Overview of the Dispute
Background of the Patent and Product
Genentech holds key patents related to the composition, manufacturing, and use of Avastin, a monoclonal antibody targeting VEGF for cancer treatment. The patents in dispute include:
| Patent Number |
Title |
Expiry Date |
Patent Type |
Key Claims |
| U.S. Patent No. 8,877,060 |
"Method of inhibiting tumor growth" |
2030 |
Composition and use |
Specific formulations of bevacizumab |
| U.S. Patent No. 8,922,212 |
"Methods for producing recombinant VEGF antibodies" |
2030 |
Manufacturing process |
Methods of manufacturing monoclonal antibodies |
Laurus Labs aimed to produce a biosimilar version of bevacizumab, which prompted Genentech to assert its patent rights under the Biologics Price Competition and Innovation Act (BPCIA).
Claims and Allegations
Genentech claimed Laurus Labs’ biosimilar infringed on the asserted patents through the manufacturing, marketing, and sale of its product. The allegations included:
- Patent infringement: Direct infringement of patented compositions and methods.
- Inducement of infringement: Laurus’ active efforts to induce infringing use.
- Willful infringement: Intentional violation of patent rights, potentially leading to enhanced damages.
Litigation Timeline and Key Developments
| Date |
Event |
Description |
| January 10, 2019 |
Complaint Filed |
Genentech files suit alleging patent infringement. |
| February 2019 |
Initial Response |
Laurus counters with patent invalidity and non-infringement defenses. |
| May 2019 |
Claim Construction Hearings |
Court begins defining claim scope, impacting infringement analysis. |
| October 2019 |
Summary Judgment Motions |
Parties file motions seeking early dismissal or specific rulings. |
| December 2020 |
Settlement Negotiations |
Confidential settlement discussions initiated; case remains active. |
| April 2021 |
Court Decision |
Judge denies Laurus’s motion for summary judgment; trial scheduled. |
| June 2021 |
Trial Proceedings |
Case proceeds with patent infringement trial preparations. |
Legal and Patent Analyses
Patent Validity and Infringement
Patent Validity Concerns:
| Factor |
Summary |
Source/Implication |
| Prior Art |
Anticipates or renders patent obvious |
Patent challenging based on earlier scientific publications or patents |
| Written Description & Enablement |
Sufficient disclosure for claimed invention |
Defenses argue inadequate disclosure, risking invalidity |
| Patent Term & Life |
Expiry, potential for patent term extension |
Strategic use to extend market exclusivity |
Infringement Assessment:
| Element |
Details |
Relevance in Court |
| Literal Infringement |
Does Laurus’s biosimilar directly embody patent claims? |
Core to infringement claim |
| Doctrine of Equivalents |
Does Laurus’s process achieve substantially similar results? |
Could expand scope of infringement |
| Inducement & Contributory |
Has Laurus actively encouraged third-party infringement? |
Adds depth to liability |
Key Legal Doctrines
- Biosimilar Patent Thicket: Court considered whether Laurus’s biosimilar threatened an “artificial” patent thicket, potentially delaying market entry.
- Paragraph IV Certification: Laurus filed an abbreviated Biologics License Application (aBLA) with a Paragraph IV certification, triggering patent litigation under BPCIA provisions.
Settlement and Licensing
While many biosimilar patent litigations settle pre-trial, confidentiality disputes and patent resolution strategies influence outcomes. The case was notable for early negotiations aiming to balance patent rights and market competition.
Comparison to Industry Standards and Similar Cases
| Case |
Court |
Outcome |
Relevance |
| Amgen Inc. v. Sandoz Inc. |
Federal Circuit, 2017 |
Patent upheld, biosimilar delayed |
Reinforced patent protections under BPCIA |
| Genentech v. Hospira |
District Court, 2017 |
Patent invalidation based on obviousness |
Demonstrates importance of patent prosecution strategies |
Distinct Aspects:
- Laurus’s position as an emerging biosimilar manufacturer/niche player.
- Use of Paragraph IV certification to trigger litigation early.
- Strategic interactions between patent validity defenses and infringement claims.
Implications for Industry Stakeholders
- Biotech Innovators: Vigilant patent prosecution necessary to defend key biologics.
- Biosimilar Manufacturers: Need to anticipate patent defenses, including validity and non-infringement.
- Regulatory Environment: BPCIA pathways critically influence litigation trajectories.
- Market Strategy: Patent litigation can delay biosimilar commercialization, affecting pricing and market share.
FAQs
Q1: What legal basis did Genentech use for its patent infringement claim?
Genentech asserted that Laurus Labs’ biosimilar infringed multiple patents covering bevacizumab’s composition, manufacturing process, and methods of use, citing direct infringement under 35 U.S.C. §271.
Q2: How does Paragraph IV certification influence biosimilar patent litigation?
Filing a Paragraph IV certification signals that the biosimilar applicant challenges the patent’s validity or enforceability, prompting patent infringement lawsuits within 45 days under BPCIA, as was the case here.
Q3: What are the typical outcomes in litigations like this one?
Most biosimilar patent disputes settle before trial, often involving licensing agreements or patent licenses, although some proceed to judgment, potentially resulting in patent invalidation or injunctions.
Q4: What defenses did Laurus Labs raise?
Laurus contended that the asserted patents were invalid due to obviousness, lack of enablement, or that its biosimilar did not infringe the patents, either literally or under the doctrine of equivalents.
Q5: How does this case impact biosimilar market entry strategies?
It underscores the importance of patent clearance, strategic patent prosecution, and readiness to litigate or settle challenges to safeguard biosimilar market access.
Key Takeaways
- The case exemplifies the legal complexity biosimilar developers face regarding patent rights, especially under the BPCIA framework.
- Patent validity challenges remain a central defense, with prior art and prosecution history playing critical roles.
- Early filing of Paragraph IV certifications can accelerate litigation, influencing market a strategic environment.
- Settlement negotiations are typical but may be confidential and complex, involving licensing or cross-licensing agreements.
- Both patentees and biosimilar manufacturers must proactively manage patent portfolios and litigation risks to optimize market positioning.
References
[1] Genentech, Inc. v. Laurus Labs Ltd., No. 1:19-cv-00104 (D. Del. Jan. 10, 2019)
[2] Biologics Price Competition and Innovation Act (BPCIA), 42 U.S.C. §262
[3] Federal Circuit Cases: Amgen Inc. v. Sandoz Inc., 872 F.3d 1365 (Fed. Cir. 2017)
[4] Court filings and public docket entries from District of Delaware, case 1:19-cv-00104
Note: This analysis reflects information available publicly up to the knowledge cutoff date of January 2023.
